These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38438797)

  • 1. Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs.
    Sharma A; Kumar N; Parachuri N; Bandello F; Loewenstein A; Kuppermann BD
    Eye (Lond); 2024 Jul; 38(10):1796-1798. PubMed ID: 38438797
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration.
    Holz FG; Oleksy P; Ricci F; Kaiser PK; Kiefer J; Schmitz-Valckenberg S;
    Ophthalmology; 2022 Jan; 129(1):54-63. PubMed ID: 33957183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
    Woo SJ; Veith M; Hamouz J; Ernest J; Zalewski D; Studnicka J; Vajas A; Papp A; Gabor V; Luu J; Matuskova V; Yoon YH; Pregun T; Kim T; Shin D; Bressler NM
    JAMA Ophthalmol; 2021 Jan; 139(1):68-76. PubMed ID: 33211076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visual Outcome and Fluid Changes Between Eyes With Polypoidal Choroidal Vasculopathy Receiving Biosimilar CKD-701 or Reference Ranibizumab Therapy: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial.
    Nam KT; Yun C; Lee YJ; Choi M; Kang D; Oh J
    Curr Eye Res; 2024 Jun; 49(6):663-670. PubMed ID: 38450631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration.
    Sunaga T; Maeda M; Saulle R; Ng SM; Sato MT; Hasegawa T; Mason AN; Noma H; Ota E
    Cochrane Database Syst Rev; 2024 Jun; 6(6):CD015804. PubMed ID: 38829176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars for Retinal Diseases: An Update.
    Sharma A; Kumar N; Parachuri N; Bandello F; Kuppermann BD; Loewenstein A
    Am J Ophthalmol; 2021 Apr; 224():36-42. PubMed ID: 33309691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study).
    Sharma A; Kumar N; Parachuri N; Bandello F; Kuppermann BD; Loewenstein A
    Eye (Lond); 2022 May; 36(5):1106-1107. PubMed ID: 34158653
    [No Abstract]   [Full Text] [Related]  

  • 8. The Biosimilar Paradox: How Anti-Vascular Endothelial Growth Factor Biosimilars Could Increase Patient and Overall Health Care Costs.
    Zhang C; Friedman S; Mruthyunjaya P; Parikh R
    Ophthalmology; 2023 Sep; 130(9):966-972. PubMed ID: 37116720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranibizumab for myopic choroidal neovascularization.
    Ng DSC; Fung NSK; Yip FLT; Lai TYY
    Expert Opin Biol Ther; 2020 Dec; 20(12):1385-1393. PubMed ID: 33003962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes.
    Bressler NM; Veith M; Hamouz J; Ernest J; Zalewski D; Studnička J; Vajas A; Papp A; Vogt G; Luu J; Matuskova V; Yoon YH; Pregun T; Kim T; Shin D; Oh I; Jeong H; Kim MY; Woo SJ
    Br J Ophthalmol; 2023 Mar; 107(3):384-391. PubMed ID: 34656987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of baseline factors with 1-year outcomes in the SB11-ranibizumab equivalence trial: A post hoc analysis.
    Woo SJ; Jung JA; Kim T; Oh I; Kim MY; Bressler NM
    Asia Pac J Ophthalmol (Phila); 2024; 13(3):100069. PubMed ID: 38759795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Treatment for Proliferative Diabetic Retinopathy: Anti-Vascular Endothelial Growth Factor Therapy.
    Gross JG; Glassman AR
    JAMA Ophthalmol; 2016 Jan; 134(1):13-4. PubMed ID: 26583372
    [No Abstract]   [Full Text] [Related]  

  • 13. Biosimilar Ranibizumab (SB11) vs Reference Ranibizumab-Diving Deeper for Safety and Efficacy.
    Sharma A; Kumar N; Parachuri N
    JAMA Ophthalmol; 2021 Jun; 139(6):677-679. PubMed ID: 33914017
    [No Abstract]   [Full Text] [Related]  

  • 14. Biosimilar Ranibizumab (SB11) vs Reference Ranibizumab-Diving Deeper for Safety and Efficacy-Reply.
    Bressler NM
    JAMA Ophthalmol; 2021 Jun; 139(6):678-679. PubMed ID: 33914021
    [No Abstract]   [Full Text] [Related]  

  • 15. Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South Asia.
    Sharma A; Kumar N; Parachuri N; Loewenstein A; Bandello F; Kuppermann BD
    Expert Opin Biol Ther; 2023; 23(8):689-692. PubMed ID: 37470687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Kim LN; Mehta H; Barthelmes D; Nguyen V; Gillies MC
    Retina; 2016 Aug; 36(8):1418-31. PubMed ID: 27388744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.
    Sheth JU; Stewart MW; Khatri M; Gupta SR; Chawla S; Rajendran A; Narayanan R
    Indian J Ophthalmol; 2021 Feb; 69(2):352-356. PubMed ID: 33463590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interim Safety Data Comparing Ranibizumab With Panretinal Photocoagulation Among Participants With Proliferative Diabetic Retinopathy.
    Gross JG; Glassman AR; Klein MJ; Jampol LM; Ferris FL; Bressler NM; Beck RW
    JAMA Ophthalmol; 2017 Jun; 135(6):672-673. PubMed ID: 28492921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranibizumab Biosimilars in Treating Retinal Disorders: A Cost-Effective Revolution?
    Chatzimichail E; Pfau K; Gatzioufas Z; Panos GD
    Drug Des Devel Ther; 2024; 18():365-374. PubMed ID: 38347957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.